LXRX Stock Forecast: Lexicon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.53
−8.38% on the day

The median 12-month analyst price target for Lexicon Pharmaceuticals, Inc. is $4.7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 69 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$743.5M
Ticker Nerd rank
69/ 100
Median analyst target
$4.70
Analysts covering
6
Revenue$692K−97.6% y/y
Operating income−$26.5M
Net income−$31.8M
Free cash flow−$9.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.5%
1M
−3.2%
YTD
+33.0%
1Y
+15.9%
From 52W high
−42.0%
From 52W low
+34.2%
$1.14
$2.64
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Lexicon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
69/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
90
Value
79
Momentum
74
Accruals
57
Volatility
55
Issuance
50
Revisions
49
Growth
27

Quality (90): The business earns solid, repeatable profits on what it owns.

Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LXRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LXRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26LXRXHigh $8.00Median $4.70Low $1.69

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
4
Buy
2
Hold
0
Sell
$1.69
Low
$4.70
Median
$8.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Nov 2026CitigroupMaintainsBuy$3.10 → $3.40
28 Sept 2026Cantor FitzgeraldInitiatesOverweight$8.00
11 May 2026CitigroupMaintainsBuy$2.30 → $3.10
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
10 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026HC Wainwright & Co.MaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025CitigroupMaintainsBuy—
24 June 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025NeedhamReiteratesHold—
7 Mar 2025Piper SandlerMaintainsOverweight—
4 Mar 2025Leerink PartnersDowngradeMarket Perform—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025NeedhamReiteratesHold—
29 Jan 2025HC Wainwright & Co.ReiteratesBuy—
29 Jan 2025NeedhamReiteratesHold—
23 Dec 2024NeedhamReiteratesHold—
25 Nov 2024NeedhamReiteratesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LXRX.

Market Radar

This page is one stock. Monday covers all of them.

LXRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LXRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Lexicon Pharmaceuticals, Inc. returned +15.9% against +6.9% for the S&P 500, dividends included.

LXRX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26LXRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LXRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
19.4×

Cheaper than 8% of US stocks

Price / book
4.6×

Cheaper than 20% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
94.4%

Higher than 98% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−43.9%

Higher than 23% of US stocks

Return on assets
−15.9%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lexicon Pharmaceuticals, Inc. has a market value of $743.5M and an enterprise value of $619.9M.

  • Revenue in the twelve months to 30 June 2026: $41.5M. The latest quarter shrank 97.6% year on year.

  • Net income over the same four quarters: −$61.1M, a −147.4% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.15.

  • Free cash flow in the twelve months to 30 June 2026: −$65.0M.

  • Shares outstanding: 444.9M.

  • Lexicon Pharmaceuticals, Inc. employs 81 people — $512K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

LXRX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LXRXLexicon Pharmaceuticals, Inc.$743.5M69
OABIOmniAb, Inc.$677.5M99
ATTOAttovia Therapeutics, Inc.$688.2M4
APMDApnimed, Inc.$669.7M4
NVCTNuvectis Pharma, Inc.$666.8M50
SLDBSolid Biosciences, Inc.$697.6M43
AURAAura Biosciences, Inc.$710.3M61

Take a look at LXRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Lexicon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LXRX

What is the LXRX stock price forecast for 2026-2027?

The median 12-month analyst price target for Lexicon Pharmaceuticals, Inc. is $4.7, with estimates ranging from $1.69 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LXRX stock a buy right now?

Of the 6 analysts covering Lexicon Pharmaceuticals, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexicon Pharmaceuticals, Inc. 69 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LXRX?

As at 21 Nov 2026, Lexicon Pharmaceuticals, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).

Will LXRX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts is $4.7, and Ticker Nerd's factor model ranks Lexicon Pharmaceuticals, Inc. 69 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LXRX stock forecast for 2030?

No analyst covering Lexicon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LXRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.69 to $8 over the next 12 months.

How has LXRX stock performed over the past year?

Lexicon Pharmaceuticals, Inc. returned +15.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lexicon Pharmaceuticals, Inc. do?

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. The company’s current portfolio centers on therapies for cardiometabolic disorders, neuropathic pain, and other chronic conditions, with products and candidates spanning commercial, clinical, and preclinical stages.

Company

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. The company’s current portfolio centers on therapies for cardiometabolic disorders, neuropathic pain, and other chronic conditions, with products and candidates spanning commercial, clinical, and preclinical stages. Its marketed medicine INPEFA (sotagliflozin) is used in cardiometabolic care, while development programs include pilavapadin for neuropathic pain and LX9851 for obesity and related metabolic disorders. Lexicon Pharmaceuticals also applies its gene-science and target-biology expertise to advance drug candidates aimed at genetically defined pathways, reflecting a research-driven model that links discovery with commercialization. Headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals serves the specialty pharmaceutical market through a focused pipeline designed for patients with serious, long-term medical needs.

CEO Dr. Michael S. Exton Ph.D. · 81 employees · United States · https://www.lexpharma.com